Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Net Cash Flow (2017 - 2025)

Cue Biopharma (CUE) has disclosed Net Cash Flow for 9 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 254.96% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 million through Dec 2025, up 117.96% year-over-year, with the annual reading at $4.7 million for FY2025, 117.96% up from the prior year.
  • Net Cash Flow hit $15.4 million in Q4 2025 for Cue Biopharma, up from -$15.8 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $21.9 million in Q4 2022 to a low of -$36.4 million in Q3 2022.
  • Historically, Net Cash Flow has averaged -$2.4 million across 5 years, with a median of -$2.5 million in 2021.
  • Biggest five-year swings in Net Cash Flow: soared 770.93% in 2022 and later tumbled 760.16% in 2025.
  • Year by year, Net Cash Flow stood at -$3.3 million in 2021, then skyrocketed by 770.93% to $21.9 million in 2022, then plummeted by 128.22% to -$6.2 million in 2023, then crashed by 61.29% to -$10.0 million in 2024, then soared by 254.96% to $15.4 million in 2025.
  • Business Quant data shows Net Cash Flow for CUE at $15.4 million in Q4 2025, -$15.8 million in Q3 2025, and $14.4 million in Q2 2025.